8,652 HFMD cases in Johor, fifth highest

JOHOR BAHRU, Aug 1 (Bernama) — Johor is ranked fifth among the states with a high cumulative number of hand, foot and mouth disease (HFMD) cases since Jan 1 until July 29, this year.

State Health and Unity Committee chairman, Ling Tian Soon said a total of 8,652 cases were reported during the period, an increase of 81.6 times compared to 106 cases for the same period last year.

He said the other states that recorded a high number of cumulative cases were Selangor with 35,575, Perak (13,487), Federal Territories (13,434) and Sarawak (8,727).

“This increase has been projected to happen this year due to relaxation of the standard operating procedure and in line with the rise in cases in Malaysia. However, the situation is still under control.

“This is proven by the significant decrease in the trend of HFMD cases reported in Johor starting from the Epidemiology Week (ME) 22/2022 until ME30/2022,” he said in a statement, here, today.

Ling said most of the HFMD cases in Johor involved children under the age of six, with 7,451 cases, followed by 1,033 cases among those aged seven to 12 and the rest were aged over 13.

He said the district of Johor Bahru recorded the highest number of cases at 2,989, Kluang (1,119), Tangkak (888), Batu Pahat (887), Segamat (775), Kota Tinggi (690), Pontian (578), Muar (330), Kulai (269) and Mersing (127).

“Until now, only two active outbreaks of HFMD were reported in the state involving Johor Bahru district,” he added.

Source: BERNAMA News Agency

New Parit Buntar Hospital on track for 2023 completion

PARIT BUNTAR, July 7 (Bernama) – Shortage of workers, land stability and the COVID-19 pandemic are reasons for the delay in the construction of the Parit Buntar Hospital, which was supposed to have been completed in December 2020.

Deputy Health Minister Datuk Dr Noor Azmi Ghazali said despite those issues, construction was now at 64 per cent with completion scheduled for May 17, 2023.

“The contractors are working hard to complete the project with some 150 workers working till late at night. They have also given the assurance that the four-storey building will be completed as scheduled,” he told a media conference after a visit to the project site here today.

The RM136 million project kicked off in June 2018 and was supposed to have been completed in December 2020.

“Folks in Krian district have been asking when will the hospital be completed so that they can get to enjoy modern and efficient facilities.

“Also, it may no longer be relevant to name it Parit Buntar Hospital as it is now located in the Bagan Serai area. We will change its name once the project is fully completed,” he said.

Meanwhile, Dr Noor Azmi has advised Malaysians not to visit places where monkeypox cases were prevalent such as Europe and the United States.

He said currently, the country’s entry points were being tightly monitored by the Health Ministry.

Singapore yesterday confirmed its first local case of monkeypox, involving a 45-year-old Malaysian man residing in the republic.

Source: BERNAMA News Agency

MOH grants conditional approval of Veklury for COVID-19 treatment

KUALA LUMPUR, July 7 (Bernama) — The Health Ministry (MOH) has granted a conditional registration approval for Veklury (remdesivir) for the emergency treatment of COVID-19.

Health director-general Tan Sri Dr Noor Hisham Abdullah said the treatment was agreed and approved at the 374th Drug Control Authority (DCA) meeting which convened today.

However, he said the product was not intended to be used to replace COVID-19 vaccines or public health measures, especially regarding compliance with standard operating procedures (SOPs).

“The MOH wishes to inform that this conditional registration approval requires that information on the quality, safety and effectiveness of antivirus products be monitored and evaluated continuously by the National Pharmaceutical Regulatory Division (NPRA) based on the latest data from time to time.

“This is to ensure that the benefit over risk comparison for the product remains positive,” he said in a statement here today.

Dr Noor Hisham said the MOH remained committed to improving the people’s access to medicines for the purpose of treatment or prevention of COVID-19 transmission in Malaysia by ensuring that they were properly evaluated based on quality, safety and effectiveness.

Veklury is indicated for COVID-19 treatment in adults and pediatric patients, aged 12 and older and weighing at least 40 kilogrammes (kg) with positive SARS-CoV-2 viral test results, hospitalised, or not hospitalised and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19 including hospitalisation or death.

In a separate statement, Dr Noor Hisham said the DCA also approved the conditional registration of a new fixed-dose combination product for HIV-1 treatment, namely TELDY Film-Coated Tablets (TELDY).

He said TELDY contained a combination of three active ingredients involving dolutegravir 50 milligrammes (mg), lamivudine (300mg) and tenofovir disoproxil fumarate (300mg), adding that the product is manufactured by Hetero Labs Limited, India while Camber Laboratories Sdn Bhd is its registration holder in Malaysia.

The NPRA evaluation on the quality, safety and efficacy data of TELDY products was found to be satisfactory for use on its own as a complete regimen for the treatment of HIV-1 infection among adults and adolescents aged 12 years and above who weigh 40 kg or more,” he said.

He said TELDY, the first dolutegravir-based combination product registered in the country was a benefit from the Voluntary Licensing (VL) agreement between Medicines Patent Pool (MPP) and dolutegravir patent owner ViiV Healthcare.

He said the VL agreement enables HIV patients’ access to dolutegravir-based products to be enhanced in line with World Health Organisation’s (WHO) recommendation on the use of the substance as the primary treatment for HIV patients.

“MOH through NPRA will continue to monitor and evaluate the latest data on the quality, safety and effectiveness of TELDY products, from time to time, to ensure that the benefit-risk balance remains positive,” said Dr Noor Hisham.

Source: BERNAMA News Agency

Sarawak Infectious Disease Research Centre expected to be ready by 2024

KOTA SAMARAHAN, July 6 (Bernama) — Construction of the Sarawak Infectious Disease Research Centre here has started and the project is expected to be completed in 2024.

State Education, Innovation and Talent Development Minister, Datuk Roland Sagah Wee Inn said the RM200 million project, on a 16-hectare site next to the Sarawak Heart Centre, included a sum of RM4 million for preparing the site alone.

“This also involves providing a safe area and a large field for a field hospital,” he told reporters after attending the project site handing-over ceremony, today.

The project, inspired by Sarawak Premier, Tan Sri Abang Johari Tun Openg, is aimed at creating a research centre for various diseases such as COVID-19, rabies, malaria, severe acute respiratory syndrome (SARS) and tuberculosis.

“It will be collaborating in research work with the Swiss Tropical Disease Research Centre in Switzerland and Imperial College London,” said Sagah, adding that the centre would give an opportunity for local medical experts to conduct research in their respective fields.

Source: BERNAMA News Agency

Malaysia Reports 2,425 New COVID-19 Infections, Four More Deaths

KUALA LUMPUR, Malaysia reported 2,425 new COVID-19 infections as of midnight, bringing the national total to 4,547,051, according to the Health Ministry.

There are eight new imported cases, with 2,417 cases being local transmissions, data released on the ministry’s website showed.

Four more deaths have been reported, bringing the death toll to 35,741.

The ministry reported 1,550 new recoveries, bringing the total number of cured and discharged to 4,484,284.

There are 27,026 active cases, with 30 being held in intensive care and 16 of those in need of assisted breathing.

A total of 8,685 vaccine doses were administered yesterday. 85.8 percent of the population have received at least one dose, 83.4 percent are fully vaccinated and 49.4 percent have received boosters.

Source: NAM NEWS NETWORK

UMNO members should support leadership of Ismail Sabri as Prime Minister – Annuar

KUALA LUMPUR, UMNO members should support the leadership of Datuk Seri Ismail Sabri Yaakob as Prime Minister who succeeded in leading the country by resolving various very challenging issues which have not been confronted by any other Prime Ministers.

Communications and Multimedia Minister Tan Sri Annuar Musa said the action of some party members in belittling the ninth Prime Minister did not show any good party spirit.

“Are we not shame that our party people are trying to weaken the PM (Prime Minister) who is from our party with only 38 seats?,” he told a media conference.

Annuar said the leadership of Ismail Sabri should be supported as he had to handle various issues among them, the COVID-19 pandemic, managing the impact of rising oil prices and uniting the cooperation of government and opposition through the Memorandum Of Understanding (MoU).

“These matters put PM Datuk Seri Ismail Sabri from UMNO in a situation which has never been experienced by any other PMs. So it is not appropriate to run down the PM from your own party, the PM endorsed by UMNO and represents UMNO,” he said.

He was commenting on the statement of Johor UMNO Liaison Committee deputy chairman Datuk Nur Jazlan Mohamed who was reported as labeling Ismail Sabri as the weakest Prime Minister from UMNO in the country’s history as he allegedly could not make decisions or stamp his power.

Annuar said even though each quarter is free to issue its personal view, Nur Jazlan is seen as having a handicap in making the evaluation.

“He (Nur Jazlan) is not in the government so there are many things he is not aware of… as he is not close to the PM, there is much more he does not know, and if he has a motive, he is therefore, influenced by his own political inclination.

“How is the PM going to represent his party which has only 38 seats besides battling COVID-19 and the economic challenges, we should assist and be sympathetic to him, instead of making baseless allegations,” said the Ketereh MP.

Annuar also questioned the actions of some UMNO members who attempted to weaken the leader from their own party when others are giving support to the prime minister’s leadership.

Source: BERNAMA News Agency

Southeast Asia, Latin America Set to Gain in Post-Pandemic Supply Chains

TAIPEI, TAIWAN — From multinational makers of clothing to consumer electronics, companies are reassessing their sources of raw materials, parts and factory assembly because of the pandemic, experts say.

That means countries in Southeast Asia and Latin America are becoming key go-to places in the global supply chain as businesses shift away from China post-pandemic.

China had attracted foreign-invested factories since the 1980s for cheap labor and high productivity. But since the pandemic, China’s traditional role as the world’s factory will be reduced, as American and European multinationals look for parts, labor and assembly at home for higher-end goods — nearby or wherever subsidies are available — according to Jayant Menon, a visiting senior fellow with the ISEAS-Yusof Ishak Institute’s Regional Economic Studies Program in Singapore.

“Countries like China that mismanage COVID will suffer greatly,” Menon told VOA via WhatsApp. “That’s because their zero COVID approach has been very disruptive to supply chains.”

While Southeast Asian countries including Vietnam, Thailand and Indonesia have been lifting pandemic restrictions this year, China reinstated lockdowns in two major cities. The lockdowns upset factory orders — and raised consumer prices — because of shipping slowdowns and worker shortages.

Seeking alternatives to China

In addition to pandemic-related disruptions in China, delays caused by worker shortages at major global ports and airports, including South Korea and the United States, have stifled the flow of consumer goods into Europe, North America and parts of Asia.

Taiwan-based PC developer Acer, for example, is addressing lockdown-driven supply chain problems by qualifying “second sources for materials where needed,” a spokesperson told VOA. The world’s No. 5 PC vendor by market share manufactures largely in China. The second sources will “come from various countries,” the spokesperson said without giving details.

American firms intend to stay in China overall but diversify, said Douglas Barry, communications vice president with the U.S.-China Business Council advocacy group in Washington. “We hear over and over that it’s a mistake to put all your eggs in one basket,” Barry said. “China’s response to COVID and growing geopolitical tensions are reminders of this truism.”

Southeast Asia

Nations such as Vietnam and Thailand were taking business from China before 2020, as investors faced rising Chinese labor costs and higher tariffs thanks to the Sino-U.S. trade dispute that began in 2018.

“I think Southeast Asia will clearly be a beneficiary of all this reconfiguration taking place. Countries like Vietnam, and to a lesser extent Thailand and Malaysia, have already seen gains from restructuring of supply chains,” Menon said.

Vietnam, he said, has a lead because of its workforce talent, pro-business reforms and network of free trade agreements. Electronics giant Samsung and American chip developer Intel both operate in Vietnam, as do foreign-invested car factories.

Malaysia is trying to capture more multinational tech, he noted. Last month, a subsidiary of giant Taiwanese electronics assembler Foxconn Technology signed an agreement with its Malaysian partner Dagang NeXchange to set up a factory, possibly for electric vehicles.

Malaysia, along with Thailand, Indonesia and the Philippines, offer “moderate wages” compared to China, said Rajiv Biswas, Asia-Pacific chief economist with S&P Global Market Intelligence in Singapore.

Multinationals, he said, are likely to expand industrial capacity in multiple places but stay in China for its market of a billion-plus people.

“They will still continue producing in China, but they will create additional production capacity in other hubs, and because of what we’ve seen during the pandemic when you can see disruptions in multiple locations, the resilience in the supply chain comes from having multiple production facilities, which also, I think, includes producing outside of Asia,” Biswas said.

Latin America

In Latin America, especially its industrial hub Mexico, products have been selling to the all-important U.S. market as a border nation. Mexico stands to benefit more from a trend known as near-shoring, analysts say.

A shared border, common time zones and linguistic similarities bring Mexico especially close to the United States, said Evan Ellis, a research professor of Latin American studies at the U.S. Army War College Strategic Studies Institute. The workforce is relatively educated, too, he said.

“Mexico is generally more accessible to many businesses in the United States in terms of the language and the culture and things than, for example, setting up shop in some cases in an Asian country or some other country that’s out of the hemisphere,” Ellis said.

Mexico has attracted American firms since the 1990s and retains “strong advantages,” Ellis said, but drug crimes and electricity costs loom as drawbacks.

Mexico is enticing some investors because its goods can enter the United States duty free under trade agreement rules, communications executive Barry said.

Brazil makes sense for companies that need its natural resources, such as ore or petroleum — or that sell cars for example — to its market of 212 million people, many in middle class cities, Ellis said. He noted that costs and regulations, however, challenge investors in Brazil.

“Manufactures are competing for limited supply of key commodities and logistical capacity, leading to consumers experiencing empty shelves and long purchase lead times,” stated professional services firm KPMG on its website. Now, it adds, “industry is evaluating and investing in their long-term supply chain strategies, paving the way for a new post pandemic normal,” which includes finding alternative customers, markets and suppliers to avoid overdependence on just one.

Source: Voice of America